Screener
Gyre Therapeutics, Inc. GYRE Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
| Line item | Six Months Ended June 30, | Six Months Ended June 30, | Six Months Ended June 30, |
|---|---|---|---|
| Purchase of property and equipment | (440) | (457) | |
| Proceeds from sale of equipment | 13 | 19 | |
| Proceeds from maturity of certificates of deposit | 12,997 | 23,190 | |
| Net cash provided by investing activities | 6,702 | 3,321 | |
| Financing Activities | |||
| Payments of listing expense | (208) | (2,106) | |
| Deferred financing costs paid | — | (1,802) | |
| Proceeds from the exercise of stock options | 221 | 1,988 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s investing cash flow?
- Gyre Therapeutics, Inc. (GYRE) reported investing cash flow of $9.76M in Q2 2026.
- How has Gyre Therapeutics, Inc.'s investing cash flow changed year-over-year?
- Gyre Therapeutics, Inc.'s investing cash flow increased by 620.6% year-over-year, from $1.35M to $9.76M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s investing cash flow?
- Over 3 years (2021 to 2024), Gyre Therapeutics, Inc.'s investing cash flow has grown at a -25.6% compound annual growth rate (CAGR), from $48.19M to -$19.88M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Gyre Therapeutics, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude